Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Federica D'Incà
Crizotinib in MET Deregulated or ROS1 Rearranged Pretreated Non-Small-Cell Lung Cancer (METROS): A Phase II, Prospective, Multicentre, Two-Arms Trial
Clinical Cancer Research
Cancer Research
Oncology
Related publications
Alectinib in ALK -Positive, Crizotinib-Resistant, Non-Small-Cell Lung Cancer: A Single-Group, Multicentre, Phase 2 Trial
The Lancet Oncology
Oncology
P2.01-50 Thromboembolism in ROS1 Rearranged Non-Small Cell Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P1.01-15 ROS1-Rearranged Non-Small Cell Lung Cancer Is Associated With High Rate of Venous Thromboembolism: Analysis of the METROS Trial
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Crizotinib Improves Osteoarthritis Symptoms in a ROS1-Fusion Advanced Non–Small Cell Lung Cancer Patient
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Erlotinib Treatment in Pretreated Patients With Non-Small Cell Lung Cancer: A Phase II Study
Oncology Letters
Cancer Research
Oncology
P1.01-78 the Incidence of Brain Metastases in ROS1-Rearranged Non-Small Cell Lung Cancer at Diagnosis and Following Progression on Crizotinib
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
OA06 Tepotinib in Non-Small Cell Lung Cancer With MET Exon 14-Skipping Mutations or MET Amplification: A Phase 2 Trial in Progress
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Nitroglycerin as a Radiosensitizer in Non-Small Cell Lung Cancer: Results of a Prospective Imaging-Based Phase II Trial
Clinical and Translational Radiation Oncology
Nuclear Medicine
Radiology
Imaging
Oncology
A Phase II Trial of Erlotinib Monotherapy for Pretreated Elderly Patients With Advanced EGFR Wild-Type Non-Small Cell Lung Cancer
BMC Research Notes
Biochemistry
Medicine
Genetics
Molecular Biology